Login to Your Account



ThromboGenics' Ocriplasmin Filing on Track in Europe, U.S.

By Cormac Sheridan


Wednesday, August 24, 2011
Six-month follow-up data from ThromboGenics NV's Phase III program for its ophthalmology drug Ocriplasmin (microplasmin) confirm top-line data it reported last year and keep the drug on track for a regulatory filing in the coming weeks.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription